Lataa...
Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
PURPOSE: Oral agents are needed that improve glycemic control without increasing hypoglycemic events in patients with type 1 diabetes (T1D). Sotagliflozin may meet this need, because this compound lowers blood glucose through the insulin-independent mechanisms of inhibiting kidney SGLT2 and intestin...
Tallennettuna:
| Julkaisussa: | Diabetes Metab Syndr Obes |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4346285/ https://ncbi.nlm.nih.gov/pubmed/25759591 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S76342 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|